National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Slides:

Advertisements

Similar presentations

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.

Advertisements

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipoprotein(a), Cardiovascular Disease, and Contemporary Management

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention Erin D. Michos, MD, MHS, Michael J. Blaha,

Neil J. Stone et al. JACC 2014;63:

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

An assessment by the Statin Cognitive Safety Task Force: 2014 update

An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update

An assessment by the Statin Diabetes Safety Task Force: 2014 update

Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men Gloria Lena Vega, PhD, Scott M. Grundy,

A review of PCSK9 inhibition and its effects beyond LDL receptors

An Update on PCSK9 Inhibitors

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report Terry A. Jacobson, MD, Matthew K. Ito,

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C- III levels in patients from the MARINE and ANCHOR studies Christie.

Predictors of first-year statin medication discontinuation: A cohort study Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Non–high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

An assessment by the Statin Intolerance Panel: 2014 update

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a)

Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia Andrew G. Bostom,

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Contemporary Evidence-Based Guidelines

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD,

Optimal high-density lipoprotein cholesterol cutoff for predicting cardiovascular disease: Comparison of the Korean and US National Health and Nutrition.

The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study Michael Davidson, MD, Michael Stevenson, RPh, PhD, Andrew Hsieh,

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

An Update on PCSK9 Inhibitors

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Christopher S. Penet, Brian H. Annex, MD, Kelly T. Gregory, R

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Higher long-term adherence to statins in rural patients at high atherosclerotic risk Matthew R. Peverelle, MD, BBiomed, Arul Baradi, MBChB, Sarang Paleri,

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

A Clinical Pharmacist Patient-Safety Initiative to Reduce Against-Label Prescribing of Statins with Cyclosporine Donald G. Lamprecht, PharmD, Anne M.

Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia Jennifer B. Christian, PharmD, MPH, PhD, Bhakti Arondekar,

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Presentation transcript:

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew K. Ito, PharmD, Kevin C. Maki, PhD, Carl E. Orringer, MD, Harold E. Bays, MD, Peter H. Jones, MD, James M. McKenney, PharmD, Scott M. Grundy, MD, PhD, Edward A. Gill, MD, Robert A. Wild, MD, PhD, Don P. Wilson, MD, W. Virgil Brown, MD Journal of Clinical Lipidology Volume 8, Issue 5, Pages 473-488 (September 2014) DOI: 10.1016/j.jacl.2014.07.007 Copyright © 2014 National Lipid Association Terms and Conditions

Figure 1 Model of steps in lifestyle therapies. ∗For people at high or very risk for ASCVD in whom drug therapy is indicated, it may be started concomitantly with lifestyle therapies. For other patients, a trial of lifestyle therapies should be undertaken before initiation of drug therapy. †In most cases, goal levels should be achieved in approximately 6 months. RDN, registered dietitian nutritionist. Journal of Clinical Lipidology 2014 8, 473-488DOI: (10.1016/j.jacl.2014.07.007) Copyright © 2014 National Lipid Association Terms and Conditions

Figure 2 Progression of atherogenic cholesterol-lowering drug therapy. ∗A moderate- or high-intensity statin should be first-line drug therapy for treatment of elevated levels of atherogenic cholesterol, unless contraindicated. In a patient with very high triglycerides (≥500 mg/dL), a triglyceride-lowering drug may be considered for first-line use to prevent pancreatitis. Other atherosclerotic cardiovascular disease risk factors should be managed appropriately in parallel. †In most cases, goal levels should be achieved in approximately 6 months. Journal of Clinical Lipidology 2014 8, 473-488DOI: (10.1016/j.jacl.2014.07.007) Copyright © 2014 National Lipid Association Terms and Conditions